Investor List:

Top Therapeutics Series B Investors in Boston / New England (12)

Know someone who's actively diligencing and investing? Add them to this list.
About this list
We’ve compiled a list of the top Therapeutics investors. The goal is to help Founders find the best investors to target and get introduced to.
Photo of Geoffrey Smith, Managing Partner at Digitalis Ventures
Geoffrey Smith
Digitalis Ventures·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY), Investors in Los Angeles (CA), Investors in San Francisco (CA), Investors in Boston (MA)
Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Diagnostics (Seed), Investors in Diagnostics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in Diagnostics (Series B), Investors in Diagnostics (Seed), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Diagnostics (Seed), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Diagnostics (Seed), Investors in Manufacturing (Series B), Investors in Manufacturing (Series B), Investors in Diagnostics (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in BioTech (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Digital Health (Series B), Investors in Manufacturing (Series A), Investors in Manufacturing (Series B), Investors in Manufacturing (Series A), Investors in BioTech (Series A), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Manufacturing (Seed), Investors in Digital Health (Series A), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Manufacturing (Seed), Investors in Manufacturing (Series A), Investors in Manufacturing (Seed), Investors in Health & Hospital Services (Series B), Investors in Digital Health (Seed), Investors in Health IT (Series A), Investors in Manufacturing (Series B), Investors in Health & Hospital Services (Series B), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Digital Health (Series B), Investors in Health & Hospital Services (Series A), Investors in BioTech (Seed), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Manufacturing (Series A), Investors in Manufacturing (Series B), Investors in Health & Hospital Services (Seed), Investors in BioTech (Series A), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Health & Hospital Services (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Series B), Investors in Health IT (Seed), Investors in Digital Health (Series A), Investors in Manufacturing (Seed), Investors in Manufacturing (Series A), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Digital Health (Series B), Investors in Manufacturing (Seed), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in Digital Health (Series A), Investors in Health IT (Seed), Investors in Digital Health (Seed), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Health IT (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in Health IT (Series A), Investors in Health IT (Seed), Investors in Los Angeles / Southern California (Other Lists), Investors in Boston / New England (Other Lists), Investors in New York City (Other Lists), Investors in San Francisco Bay Area (Other Lists)
Photo of Scott Biller, Venture Partner at GV (Google Ventures)
Scott Biller
GV (Google Ventures)·Venture Partner
Sweet spot: $25.0M
Range: $250K - $50.0M
Investors in Boston (MA)
Photo of Wes Schifone, Scout at CRV
Wes Schifone
CRV·Scout
Sweet spot: $50K
Range: $25K - $100K
Investors in Boston (MA)
Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Wellness & Fitness (Series B), Investors in Therapeutics (Seed), Investors in Wellness & Fitness (Series A), Investors in Wellness & Fitness (Seed), Investors in Therapeutics (Series B), Investors in Web3/Blockchain (Series B), Investors in Therapeutics (Series A), Investors in Consumer Health (Series B), Investors in Web3/Blockchain (Series A), Investors in Wellness & Fitness (Series B), Investors in Therapeutics (Seed), Investors in Consumer Health (Series A), Investors in Digital Health (Series B), Investors in Web3/Blockchain (Seed), Investors in Consumer Health (Seed), Investors in Digital Health (Series A), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Digital Health (Seed), Investors in Wellness & Fitness (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in Wellness & Fitness (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Consumer Health (Series B), Investors in Web3/Crypto (Series B), Investors in Web3/Crypto (Series A), Investors in Web3/Blockchain (Series B), Investors in Web3/Crypto (Seed), Investors in Digital Health (Series B), Investors in Consumer Health (Series A), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Web3/Crypto (Series B), Investors in Digital Health (Series A), Investors in Consumer Health (Seed), Investors in Digital Health (Seed), Investors in Web3/Blockchain (Series A), Investors in Web3/Crypto (Series A), Investors in Web3/Blockchain (Seed), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Seed), Investors in Web3/Crypto (Seed), Investors in Health IT (Seed), Investors in Boston / New England (Other Lists), Investors in Angel, Scout, and Solo-Capitalists (Other Lists)
Photo of Cavin Mozarmi, Senior Associate at REMUS Capital
Cavin Mozarmi
REMUS Capital·Senior Associate
Sweet spot: $15.0M
Range: $10.0M - $20.0M
Investors in Boston (MA)
Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Pre-seed), Investors in Therapeutics (Seed), Investors in DeepTech (Series B), Investors in DeepTech (Pre-seed), Investors in Therapeutics (Series B), Investors in DeepTech (Series A), Investors in DeepTech (Seed), Investors in Therapeutics (Pre-seed), Investors in Therapeutics (Series A), Investors in SaaS (Series B), Investors in Enterprise (Pre-seed), Investors in Enterprise (Series B), Investors in FinTech (Pre-seed), Investors in SaaS (Pre-seed), Investors in Therapeutics (Seed), Investors in SaaS (Series A), Investors in DeepTech (Series B), Investors in Enterprise (Series A), Investors in SaaS (Seed), Investors in Enterprise (Seed), Investors in DeepTech (Pre-seed), Investors in FinTech (Series B), Investors in FinTech (Series A), Investors in FinTech (Seed), Investors in Boston / New England (Other Lists), Investors in DeepTech (Series A), Investors in DeepTech (Seed), Investors in SaaS (Series B), Investors in Enterprise (Pre-seed), Investors in Enterprise (Series B), Investors in SaaS (Pre-seed), Investors in FinTech (Pre-seed), Investors in FinTech (Series B), Investors in SaaS (Series A), Investors in Enterprise (Series A), Investors in SaaS (Seed), Investors in FinTech (Series A), Investors in Enterprise (Seed), Investors in FinTech (Seed)
Photo of Derek DiRocco, Partner at RA Capital
Derek DiRocco
RA Capital·Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Boston (MA)
Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Pharmaceuticals (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Pharmaceuticals (Seed), Investors in Therapeutics (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Seed), Investors in Boston / New England (Other Lists), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in BioTech (Seed)
Photo of Jake Simson, Partner at RA Capital
Jake Simson
RA Capital·Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Boston (MA)
Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Pharmaceuticals (Series B), Investors in Therapeutics (Series A), Investors in Pharmaceuticals (Seed), Investors in Therapeutics (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series B), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in Boston / New England (Other Lists), Investors in BioTech (Series A), Investors in BioTech (Seed)
Photo of Reza Halse, Partner at RA Capital
Reza Halse
RA Capital·Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Cambridge (MA)
Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in BioTech (Series B), Investors in Therapeutics (Seed), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in BioTech (Series B), Investors in Boston / New England (Other Lists), Investors in BioTech (Series A), Investors in BioTech (Seed)
Photo of Zach Scheiner, Principal at RA Capital
Zach Scheiner
RA Capital·Principal
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Boston (MA)
Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Medical Devices (Series B), Investors in Therapeutics (Series B), Investors in Medical Devices (Series A), Investors in Medical Devices (Seed), Investors in Therapeutics (Series A), Investors in BioTech (Series B), Investors in Therapeutics (Seed), Investors in Medical Devices (Series B), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Medical Devices (Seed), Investors in Medical Devices (Series A), Investors in BioTech (Series B), Investors in Boston / New England (Other Lists), Investors in BioTech (Series A), Investors in BioTech (Seed)
Get new data & insights delivered to your inbox